FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Hans Schreiber

Research Profile

Living Beings

Chemicals & Drugs

Antigens, Neoplasm

Disorders

Anatomy

Physiology

Procedures

Phenomena

Ultraviolet Rays

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Rebecca Berlant Liu; Andrea Schietinger; Hans Schreiber; Karin Schreiber; Cezary Ciszewski; Boris Engels; Bana Jabri
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner.
Boris Engels; David M Kranz; Rebecca B Liu; Stephen C Meredith; Donald A Rowley; David C Binder; Victor H Engelhard; Alessandro Sette; John Sidney; Hans Schreiber
Relapse or eradication of cancer is predicted by Peptide-major histocompatibility complex affinity.
Rebecca B Liu; Donald A Rowley; Andrea Schietinger; Ainhoa Arina; David C Binder; Eric Butz; Boris Engels; Elizabeth Hyjek; Bana Jabri; Thomas Krausz; Karin Schreiber; Hans Schreiber
Densely granulated murine NK cells eradicate large solid tumors.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Hans Schreiber (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Rebecca Berlant Liu; Andrea Schietinger; Hans Schreiber; Karin Schreiber; Cezary Ciszewski; Boris Engels; Bana Jabri
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(20):8158-63.
2013: Boris Engels; David M Kranz; Rebecca B Liu; Stephen C Meredith; Donald A Rowley; David C Binder; Victor H Engelhard; Alessandro Sette; John Sidney; Hans Schreiber
Relapse or eradication of cancer is predicted by Peptide-major histocompatibility complex affinity.
Cancer cell 2013;23(4):516-26.
2012: Rebecca B Liu; Donald A Rowley; Andrea Schietinger; Ainhoa Arina; David C Binder; Eric Butz; Boris Engels; Elizabeth Hyjek; Bana Jabri; Thomas Krausz; Karin Schreiber; Hans Schreiber
Densely granulated murine NK cells eradicate large solid tumors.
Cancer research 2012;72(8):1964-74.
2012: Boris Engels; David M Kranz; Andrea J Sant; Adam S Chervin; Hans Schreiber
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(3):652-60.
2012: Boris Engels; Donald A Rowley; Hans Schreiber
Targeting stroma to treat cancers.
Seminars in cancer biology 2012;22(1):41-9.
2011: Terry H Wu; Karin Schreiber; Ralph R Weichselbaum; Ainhoa Arina; Elena V Efimova; Nikolai N Khodarev; Donald A Rowley; Hans Schreiber
Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.
Cancer immunity 2011;11():2.
2010: Hans Schreiber; Donald A Rowley
Cancer. Awakening immunity.
Science (New York, N.Y.) 2010;330(6005):761-2.
2010: Andrea Schietinger; Mary Philip; Rebecca B Liu; Karin Schreiber; Hans Schreiber
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.
The Journal of experimental medicine 2010;207(11):2469-77.
2010: Mary Philip; Andrea Schietinger; Hans Schreiber
Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.
Immunology 2010;130(4):494-503.
2009: Neeraj Chopra; Wenxun Gan; Hans Schreiber; Josh W Kurutz; Stephen C Meredith
Versatile cyclic templates for assembly of axially oriented ligands.
Bioconjugate chemistry 2009;20(2):231-40.
2008: H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.
The Journal of clinical investigation 2008;118(11):3574-81.
2008: Hans Schreiber
Tumor-specific immune responses.
Seminars in immunology 2008;20(5):265-6.
2008: Andrea Schietinger; Mary Philip; Hans Schreiber
Specificity in cancer immunotherapy.
Seminars in immunology 2008;20(5):276-85.
2008: Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.
The Journal of clinical investigation 2008;118(4):1398-404.
2008: Bin Zhang; Yi Zhang; Natalie A Bowerman; Andrea Schietinger; Yang-Xin Fu; David M Kranz; Donald A Rowley; Hans Schreiber
Equilibrium between host and cancer caused by effector T cells killing tumor stroma.
Cancer research 2008;68(5):1563-71.
2008: Hans Schreiber; Donald A Rowley
Cancer. Quo vadis, specificity?
Science (New York, N.Y.) 2008;319(5860):164-5.
2007: Ping Yu; Youjin Lee; Yang Wang; Xiaojuan Liu; Sogyong Auh; Thomas F Gajewski; Hans Schreiber; Zhaoyang You; Campbell Kaynor; Xinzhong Wang; Yang-Xin Fu
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(3):1960-8.
2007: Bin Zhang; Natalie A Bowerman; Joseph K Salama; Hank Schmidt; Michael T Spiotto; Andrea Schietinger; Ping Yu; Yang-Xin Fu; Ralph R Weichselbaum; Donald A Rowley; David M Kranz; Hans Schreiber
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
The Journal of experimental medicine 2007;204(1):49-55.
2006: Andrea Schietinger; Mary Philip; Barbara A Yoshida; Parastoo Azadi; Hui Liu; Stephen C Meredith; Hans Schreiber
A mutant chaperone converts a wild-type protein into a tumor-specific antigen.
Science (New York, N.Y.) 2006;314(5797):304-8.
2006: Karin Schreiber; Donald A Rowley; Gert Riethmüller; Hans Schreiber
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.
Hematology/oncology clinics of North America 2006;20(3):567-84.
2006: Michael T Spiotto; Hans Schreiber
Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombination.
Journal of immunological methods 2006;312(1-2):201-8.
2006: Ping Yu; Donald A Rowley; Yang-Xin Fu; Hans Schreiber
The role of stroma in immune recognition and destruction of well-established solid tumors.
Current opinion in immunology 2006;18(2):226-31.
2005: Barbara L F Kaplan; Tamson V Moore; Karin Schreiber; Glenda G Callender; Hans Schreiber; Michael I Nishimura
A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity.
Cancer letters 2005;224(1):153-66.
2005: Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
The Journal of experimental medicine 2005;201(5):779-91.
2005: Michael T Spiotto; Hans Schreiber
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.
Cancer immunity 2005;5():8.
2004: Mary Philip; Donald A Rowley; Hans Schreiber
Inflammation as a tumor promoter in cancer induction.
Seminars in cancer biology 2004;14(6):433-9.
2004: Karin Schreiber; Ronald E Cannon; Theodore Karrison; Gabriele Beck-Engeser; Dezheng Huo; Raymond W Tennant; Heather Jensen; W Martin Kast; Thomas Krausz; Stephen C Meredith; Lieping Chen; Hans Schreiber
Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors.
Oncogene 2004;23(22):3972-9.
2004: Michael T Spiotto; Donald A Rowley; Hans Schreiber
Bystander elimination of antigen loss variants in established tumors.
Nature medicine 2004;10(3):294-8.
2004: Terry H Wu; Christine N Pabin; Zhihai Qin; Thomas Blankenstein; Mary Philip; James J Dignam; Karin Schreiber; Hans Schreiber
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(5):3243-51.
2004: Ping Yu; Youjin Lee; Wenhua Liu; Robert K Chin; Jing Wang; Yang Wang; Andrea Schietinger; Mary Philip; Hans Schreiber; Yang-Xin Fu
Priming of naive T cells inside tumors leads to eradication of established tumors.
Nature immunology 2004;5(2):141-9.
2003: Michael T Spiotto; Yang-Xin Fu; Hans Schreiber
Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.
Current opinion in immunology 2003;15(6):725-30.
2003: Michael T Spiotto; Michael A Reth; Hans Schreiber
Genetic changes occurring in established tumors rapidly stimulate new antibody responses.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(9):5425-30.
2003: Ping Yu; Michael T Spiotto; Youjin Lee; Hans Schreiber; Yang-Xin Fu
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.
The Journal of experimental medicine 2003;197(8):985-95.
2003: Christian Beck; Karin Schreiber; Hans Schreiber; Donald A Rowley
C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum.
European journal of immunology 2003;33(1):19-28.
2002: Michael T Spiotto; Ping Yu; Donald A Rowley; Michael I Nishimura; Stephen C Meredith; Thomas F Gajewski; Yang-Xin Fu; Hans Schreiber
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
Immunity 2002;17(6):737-47.
2002: Hans Schreiber; T H Wu; J Nachman; W Martin Kast
Immunodominance and tumor escape.
Seminars in cancer biology 2002;12(1):25-31.
2001: Gabriele Beck-Engeser; P A Monach; D Mumberg; F Yang; Sherry L Wanderling; Karin Schreiber; R Espinosa; M M Le Beau; Stephen C Meredith; Hans Schreiber
Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.
The Journal of experimental medicine 2001;194(3):285-300.
2001: C Beck; Hans Schreiber; D Rowley
Role of TGF-beta in immune-evasion of cancer.
Microscopy research and technique 2001;52(4):387-95.
2000: Hans Schreiber; T H Wu; J Nachman; Donald A Rowley
Immunological enhancement of primary tumor development and its prevention.
Seminars in cancer biology 2000;10(5):351-7.
2000: CT Siegel; Karin Schreiber; Stephen C Meredith; Gabriele Beck-Engeser; David W Lancki; C A Lazarski; Yang-Xin Fu; Donald A Rowley; Hans Schreiber
Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.
The Journal of experimental medicine 2000;191(11):1945-56.
1999: D Mumberg; P A Monach; Sherry L Wanderling; Mary Philip; A Y Toledano; R D Schreiber; Hans Schreiber
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(15):8633-8.
1998: Purnima Dubey; Stephen C Meredith; CT Siegel; Hans Schreiber
Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(4):277-82.
1997: M Wick; Purnima Dubey; H Koeppen; CT Siegel; PE Fields; Lieping Chen; Jeffrey A Bluestone; Hans Schreiber
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.
The Journal of experimental medicine 1997;186(2):229-38.
1997: Purnima Dubey; Ronald Hendrickson; Stephen C Meredith; CT Siegel; Jeffrey Shabanowitz; JC Skipper; Victor H Engelhard; Donald F Hunt; Hans Schreiber
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68.
The Journal of experimental medicine 1997;185(4):695-705.
1996: L P Seung; Ralph R Weichselbaum; A Toledano; K Schreiber; Hans Schreiber
Radiation can inhibit tumor growth indirectly while depleting circulating leukocytes.
Radiation research 1996;146(6):612-8.
1996: Dominik Mumberg; M Wick; Hans Schreiber
Unique tumor antigens redefined as mutant tumor-specific antigens.
Seminars in immunology 1996;8(5):289-93.
1996: C Van Waes; P A Monach; J L Urban; R D Wortzel; Hans Schreiber
Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.
Tissue antigens 1996;47(5):399-407.
1995: L P Seung; S K Seung; Hans Schreiber
Antigenic cancer cells that escape immune destruction are stimulated by host cells.
Cancer research 1995;55(21):5094-100.
1995: L P Seung; D A Rowley; Purnima Dubey; Hans Schreiber
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(14):6254-8.
1995: L A Pekarek; B A Starr; A Y Toledano; Hans Schreiber
Inhibition of tumor growth by elimination of granulocytes.
The Journal of experimental medicine 1995;181(1):435-40.
1995: P A Monach; Stephen C Meredith; CT Siegel; Hans Schreiber
A unique tumor antigen produced by a single amino acid substitution.
Immunity 1995;2(1):45-59.
1993: M N Teng; K Turksen; C A Jacobs; Elaine Fuchs; Hans Schreiber
Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein.
Clinical immunology and immunopathology 1993;69(2):215-22.
1993: H Koeppen; M Acena; A Drolet; D A Rowley; Hans Schreiber
Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.
European journal of immunology 1993;23(11):2770-6.
1993: S Seung; J L Urban; Hans Schreiber
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
The Journal of experimental medicine 1993;178(3):933-40.
1993: H Koeppen; S Singh; Hans Schreiber
Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors.
Annals of the New York Academy of Sciences 1993;690():244-55.
1993: P A Monach; Hans Schreiber; D A Rowley
CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.
Transplantation 1993;55(6):1356-61.
1993: H Koeppen; S Singh; H J Stauss; Ben Ho Park; D A Rowley; Hans Schreiber
CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes.
Transplantation 1993;55(6):1349-55.
1993: L A Pekarek; Ralph R Weichselbaum; Michael A Beckett; James B Nachman; Hans Schreiber
Footprinting of individual tumors and their variants by constitutive cytokine expression patterns.
Cancer research 1993;53(9):1978-81.
1993: S Seung; J L Urban; Hans Schreiber
DNA sequence analysis of T-cell receptor genes reveals an oligoclonal T-cell response to a tumor with multiple target antigens.
Cancer research 1993;53(4):840-5.
1992: J Cheng; K Turksen; QC Yu; Hans Schreiber; M Teng; Elaine Fuchs
Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice.
Genes & development 1992;6(8):1444-56.
1992: J L Urban; Hans Schreiber
Tumor antigens.
Annual review of immunology 1992;10():617-44.
1992: S Singh; S R Ross; M Acena; D A Rowley; Hans Schreiber
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.
The Journal of experimental medicine 1992;175(1):139-46.
1991: P L Ward; Hans Schreiber
MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors.
Seminars in cancer biology 1991;2(5):321-8.
1991: M N Teng; Ben Ho Park; H Koeppen; Kevin Tracey; B M Fendly; Hans Schreiber
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(9):3535-9.
1990: P L Ward; H Koeppen; T Hurteau; D A Rowley; Hans Schreiber
Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
Cancer research 1990;50(13):3851-8.
1990: G A Perdrizet; S R Ross; H J Stauss; S Singh; H Koeppen; Hans Schreiber
Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen.
The Journal of experimental medicine 1990;171(4):1205-20.
1990: J D Ellenhorn; Hans Schreiber; Jeffrey A Bluestone
Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(7):2840-6.
1990: G Torre-Amione; R Daniel Beauchamp; H Koeppen; Ben Ho Park; Hans Schreiber; Harold L Moses; D A Rowley
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(4):1486-90.
1989: P L Ward; H Koeppen; T Hurteau; Hans Schreiber
Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.
The Journal of experimental medicine 1989;170(1):217-32.
1989: Craig A Mullen; D A Rowley; Hans Schreiber
Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity.
Cellular immunology 1989;119(1):101-13.
1989: Hans Schreiber; H Koeppen; P L Ward
Tumor-specific antigens and tumor-specific mutant proteins in mouse and man.
Haematology and blood transfusion 1989;32():284-8.
1988: J L Rothstein; T F Lint; Hans Schreiber
Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5).
The Journal of experimental medicine 1988;168(6):2007-21.
1988: J D Ellenhorn; R Hirsch; Hans Schreiber; Jeffrey A Bluestone
In vivo administration of anti-CD3 prevents malignant progressor tumor growth.
Science (New York, N.Y.) 1988;242(4878):569-71.
1988: J L Rothstein; Hans Schreiber
Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(2):607-11.
1988: Hans Schreiber; P L Ward; D A Rowley; H J Stauss
Unique tumor-specific antigens.
Annual review of immunology 1988;6():465-83.
1987: J L Urban; J L Rothstein; M H Shephard; Hans Schreiber
Tumor necrosis factor: a potent mediator of macrophage-dependent tumor-cell killing.
Haematology and blood transfusion 1987;31():351-4.
1987: H J Stauss; M A Fink; B Starr; Hans Schreiber
Identification of a gene encoding a tumor-specific antigen that causes tumor rejection.
Haematology and blood transfusion 1987;31():308-13.
1987: J L Rothstein; Hans Schreiber
Relationship of tumour necrosis factor and endotoxin to macrophage cytotoxicity, haemorrhagic necrosis and lethal shock.
Ciba Foundation symposium 1987;131():124-39.
1986: H J Stauss; C Van Waes; M A Fink; B Starr; Hans Schreiber
Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.
The Journal of experimental medicine 1986;164(5):1516-30.
1986: C Van Waes; J L Urban; J L Rothstein; P L Ward; Hans Schreiber
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.
The Journal of experimental medicine 1986;164(5):1547-65.
1986: J L Urban; H Michael Shepard; J L Rothstein; B J Sugarman; Hans Schreiber
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(14):5233-7.
1986: C Philipps; H J Stauss; R D Wortzel; Hans Schreiber
A novel MHC class I molecule as a tumour-specific antigen. Correlation between the antibody-defined and the CTL-defined target structure.
Journal of immunogenetics 1986;13(2-3):93-9.
1986: R D Wortzel; H J Stauss; C Van Waes; Hans Schreiber
The complexity of unique tumor-specific antigens.
Symposium on Fundamental Cancer Research 1986;38():161-82.
1985: Craig A Mullen; J L Urban; C Van Waes; D A Rowley; Hans Schreiber
Multiple cancers. Tumor burden permits the outgrowth of other cancers.
The Journal of experimental medicine 1985;162(5):1665-82.
1984: R D Wortzel; J L Urban; Hans Schreiber
Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.
Proceedings of the National Academy of Sciences of the United States of America 1984;81(7):2186-90.
1984: J L Urban; C Van Waes; Hans Schreiber
Pecking order among tumor-specific antigens.
European journal of immunology 1984;14(2):181-7.
1983: R D Wortzel; J L Urban; C Philipps; F W Fitch; Hans Schreiber
Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(5):2461-6.
1983: R D Wortzel; C Philipps; J L Urban; Hans Schreiber
Dissection of a unique tumor-specific transplantation antigen into multiple unique independent epitopes using syngeneic T-cell lines.
Haematology and blood transfusion 1983;28():489-92.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.